Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Submitted by
admin
on September 21, 2018 - 10:02am
Source:
CP WIre
News Tags:
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Headline:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
snippet:
Exelixis is eligible to receive a milestone payment of $40 million for the approval of the second-line treatment of HCC
In May of 2018, the FDA accepted for filiing an sNDA for Cabometyx for previously treated advanced HCC
A Prescription Drug User Fee Act (PDUFA) action date of January 14 was assigned
Do Not Allow Advertisers to Use My Personal information
